OR WAIT 15 SECS
Takeda Pharmaceutical and Arbor Pharmaceuticals enter into a license, development and commercialization agreement for Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone).
Takeda and Arbor Pharmaceuticals Ireland, a wholly owned subsidiary of Arbor Pharmaceuticals, have entered into a license, development, and commercialization agreement. Under which Arbor will receieve with exclusive rights to market and sell the antihypertensive drugs, Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) in the United States, effective Sept. 12, 2013.
Under the agreement, Arbor will have exclusive rights to promote and sell Edarbi and Edarbyclor in the US. In return, Takeda will receive an upfront payment along with a series of future milestone and royalty payments based upon sales of the Edarbi family of products.